GHK Peptide: Uses, Research Status, and Clinical Trials

What GHK is

GHK is a small tripeptide compound identified by the molecular formula C14H24N6O4. No FDA-approved drug label exists for GHK, so there are no established indications, dosing standards, or label-based mechanism of action to report. The compound is registered in PubChem (CID 73587) for reference, but this identifier alone does not establish any approved medical use.

Clinical trial landscape

There are 6 registered trials referencing GHK. The available trial sample reflects a mix of statuses and designs rather than a single, unified program. One early-phase study, "Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks," is currently enrolling by invitation. A separate study examining the X39 Patch and its relationship to circulating GHK and GHK-Cu levels in healthy adults has not yet begun recruiting. A third listed trial, a cluster-randomized community intervention, has been completed, though its title suggests a different research focus unrelated to peptide pharmacology. Together, these entries show that clinical investigation involving GHK is active but limited in scope and early in progression.